Astrazeneca's breast cancer drug fails late-stage trial
Astrazeneca's breast cancer drug fails late-stage trial Sept 11 (Reuters) - AstraZeneca AZN.L said on Friday its breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial.
(Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid)
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines